Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityNotes PayablesOperating LeasesOther Accumulated ExpensesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShort term DebtTotal Current LiabilitiesTotal DebtTotal Liabilities
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

China Pharma Holdings (CPHI) Current Deferred Revenue (2016 - 2025)

China Pharma Holdings (CPHI) has disclosed Current Deferred Revenue for 16 consecutive years, with $120912.0 as the latest value for Q3 2025.

  • For the quarter ending Q3 2025, Current Deferred Revenue rose 385.2% year-over-year to $120912.0, compared with a TTM value of $120912.0 through Sep 2025, up 385.2%, and an annual FY2024 reading of $162208.0, up 79.22% over the prior year.
  • Current Deferred Revenue was $120912.0 for Q3 2025 at China Pharma Holdings, up from $77683.0 in the prior quarter.
  • Across five years, Current Deferred Revenue topped out at $572013.0 in Q1 2021 and bottomed at $24920.0 in Q3 2024.
  • Average Current Deferred Revenue over 5 years is $198975.9, with a median of $136099.0 recorded in 2022.
  • The sharpest move saw Current Deferred Revenue tumbled 85.52% in 2024, then skyrocketed 385.2% in 2025.
  • Year by year, Current Deferred Revenue stood at $210028.0 in 2021, then soared by 147.73% to $520295.0 in 2022, then plummeted by 82.6% to $90507.0 in 2023, then skyrocketed by 79.22% to $162208.0 in 2024, then dropped by 25.46% to $120912.0 in 2025.
  • Business Quant data shows Current Deferred Revenue for CPHI at $120912.0 in Q3 2025, $77683.0 in Q2 2025, and $114435.0 in Q1 2025.